Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma

In aRCC patients treated with first-line pazopanib, 22% had a long-term response. Significant predictors of long-term response included an ECOG PS of 0 and a history of nephrectomy.